Healthcare enterprise Centene Corporation (NYSE:CNC) said on Tuesday that its wholly-owned subsidiary, Health Net Federal Services LLC (HNFS), has announced the receipt of the Disease Management Accreditation from URAC effective 1 October 2017 to 1 October 2020.
Founded in 1990, URAC promotes healthcare quality through accreditation, certification and measurement. Its portfolio of accreditation and certification programmes span the healthcare industry, addressing healthcare management, healthcare operations, health plans, pharmacies, telehealth providers, physician practices and more. URAC accreditation is a symbol of excellence for organizations to showcase their validated commitment to quality and accountability.
Since 2011, HNFS has continuously held URAC's Disease Management Accreditation.
HNFS' Disease Management Education Programme serves TRICARE North Prime beneficiaries, identified by the Defense Health Agency, for enrollment in healthcare management programmes targeting six conditions: anxiety, asthma, chronic obstructive pulmonary disease (COPD), congestive heart failure, depression and diabetes.
vTv Therapeutics secures USD51m private placement for cadisegliatin Phase 3 study
AbbVie names new chief executive officer
SkinBioTherapeutics expands foot care products in AMEA with Dermatonics partnership
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Insulet's Omnipod 5 integration with Abbott FreeStyle Libre 2 Plus Sensor secures CE Mark approval
Kyowa Kirin enrols first subject in phase two tivozanib eye drops (KHK4951) clinical trial
China accepts GSK's Shingrix application for at-risk adults
Novo Nordisk to boost manufacturing capacity with acquisition of three fill-finish sites
Breye Therapeutics commences phase 1b/2a danegaptide clinical trial
DexCom Inc breaks ground on new manufacturing facility in Ireland
VibroSense Dynamics AB secures provisional patent for chemotherapy-induced nerve damage prediction
Innovent Biologics signs collaboration agreement with Sanegene Bio USA
Japan approves GSK's filing for Arexvy vaccination for at-risk adults